Icon Group becomes the first international participant in the HyperArc® registry, which is sponsored by Varian and allows clinicians to treat tumors with highly conformal doses of radiation therapy. The collaboration marks the first research project for Varian’s and Icon’s global five-year strategic partnership, which includes the development of ongoing clinical and technical research programs to advance cancer care.
The automated system can even target several tumors in different locations in the brain. The Hyperarc registry will collect patient data for clinical research that will be used to inform and expand treatment options for patients with brain tumors.
The HyperArc registry will contain data collected during and after the course of radiation treatment using HyperArc on a Varian linear accelerator. It helps clinicians understand real-world use cases of HyperArc and evaluate caseloads, processes, and outcomes from treatment techniques. An automated process uploads treatment data to the registry to facilitate clinical research.
Previously many of patients with brain tumors would have had to receive radiation to the whole brain, resulting in undesirable side effects and suboptimal quality of life. Now we can treat up to 20 metastases in one treatment session, with promising results. The registry is another step forward in our ability to analyze real-world data to inform treatment pathway decisions and ultimately push the boundaries of this technology to improve patient outcomes and evolve how we treat cancer, said Associate Professor Matthew Foote, Radiation Oncologist, and Principal Investigator.
The registry will be open across multiple Icon Cancer Centre locations in Australia, with the potential to expand across the group’s international network. This multicentre approach will collect anonymized data to evaluate the comparative effectiveness, relative toxicity, and quality of care in a large cohort of patients.